PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTiragolumab
Tiragolumab
Tiragolumab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0472——9
Non-small-cell lung carcinomaD002289——144——7
Lung neoplasmsD008175—C34.90—25——6
Squamous cell carcinomaD002294——131——4
NeoplasmsD009369—C80—31——4
Small cell lung carcinomaD055752———12——3
Liver neoplasmsD008113EFO_1001513C22.0221——3
Esophageal neoplasmsD004938—C15111——2
Hepatocellular carcinomaD006528—C22.0111——2
Esophageal squamous cell carcinomaD000077277————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5012———3
Triple negative breast neoplasmsD064726——12———3
AdenocarcinomaD000230——23———3
Squamous cell carcinoma of head and neckD000077195——12———2
Small cell carcinomaD018288———1———1
Uterine cervical neoplasmsD002583———1———1
Urologic neoplasmsD014571—C64-C6811———1
Urinary bladder neoplasmsD001749—C6711———1
Transitional cell carcinomaD002295——11———1
Pancreatic neoplasmsD010190EFO_0003860C2511———1
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTiragolumab
INNtiragolumab
Description
Tiragolumab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>8JEQ:A|antibody heavy chain EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKN QFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH >8JEQ:B|antibody light chain DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLT ISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB8JEO, 8JEQ
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4298050
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID6XG22YQM2Z (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 770 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
510 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use